And, as Rosenberg asserted in his editorial, "Clearly, their data support beta-secretase activity as an important target for therapeutic intervention in Alzheimer’s. . . ." Indeed, some drug companies are searching for a compound that can counter beta-secretase activity and that might prove to be an effective and safe Alzheimer’s treatment (Psychiatric News, September 8).